Clinical Trial Update: Study of CM313(SC) Injection in Subjects With Platelet Transfusion Refractoriness [Phase 1, Phase 2]

View source ↗

Summary

This document outlines a Phase 1/2 clinical trial of CM313(SC) Injection for platelet transfusion refractoriness. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Platelet Transfusion Refractoriness

Drugs mentioned

• CM313(SC) Injection (CM313)

Snippet

Sponsor: Keymed Biosciences Co.Ltd | Conditions: Platelet Transfusion Refractoriness | Phase 1, Phase 2 | Status: RECRUITING